SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CA

在这项研究中，主要目的是评估固定 苏拉明联合雄激素抑制（睾丸切除加 氟替卡松，或LHRH激动剂加氟替卡松） 新诊断的D2期前列腺癌患者。 可行性 评价的基础是对与苏拉明有关的 神经毒性或治疗中断四周或更长时间。 还有， 还将估计无进展存活和存活。

In this study the primary objective is to assess the feasibility of fixed schedule suramine plus combined androgen suppression (orchiectomy plus flutamide, or LHRH agonist plus flutamide) in a cooperative group setting in patients with newly diagnosed Stage D2 prostate cancer. Feasibility evaluation is based on an assessment of the magnitude of suramine-related neurotoxicity or treatment interruption of four weeks or more. Also, progression-free survival and survival will also be estimated.